Indaptus Therapeutics has a quick ratio of 5.05. It generally indicates good short-term financial strength.
The historical rank and industry rank for Indaptus Therapeutics's Quick Ratio or its related term are showing as below:
INDP'
s Quick Ratio Range Over the Past 10 Years
Min: 0.86 Med: 6.5 Max: 8.77
Current: 5.05
During the past 4 years, Indaptus Therapeutics's highest Quick Ratio was 8.77. The lowest was 0.86. And the median was 6.50.
INDP's Quick Ratio is ranked better than 62.14% of 1553
companies
in the Biotechnology industry
Industry Median: 3.53
vs INDP: 5.05
Indaptus Therapeutics Quick Ratio Historical Data
The historical data trend for Indaptus Therapeutics's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Indaptus Therapeutics's Quick Ratio
For the Biotechnology subindustry, Indaptus Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Indaptus Therapeutics's Quick Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Indaptus Therapeutics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Indaptus Therapeutics's Quick Ratio falls into.
Indaptus Therapeutics Quick Ratio Calculation
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Indaptus Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Indaptus Therapeutics (NAS:INDP) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Indaptus Therapeutics Quick Ratio Related Terms
Thank you for viewing the detailed overview of Indaptus Therapeutics's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Indaptus Therapeutics (Indaptus Therapeutics) Business Description
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma in standard pre-clinical models.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
INDP has been successfully added to your 